Particle.news

Download on the App Store

Delhi High Court Bars Dr. Reddy’s and OneSource from Marketing Semaglutide

A suit by Novo Nordisk over Wegovy’s patent protection prompted the interim ban

Image
Image

Overview

  • On May 31, the Delhi High Court granted interim relief to Novo Nordisk, prohibiting the Indian firms from marketing semaglutide domestically.
  • Dr. Reddy’s and OneSource started manufacturing semaglutide under December 2024 licences and pledged not to sell the drug in India following the order.
  • Both companies reserve the right to export semaglutide to territories where Novo Nordisk holds no patent, a move Novo Nordisk argues violates the Patents Act, 1970.
  • Dr. Reddy’s has accused Novo Nordisk of evergreening by asserting that semaglutide was disclosed in an earlier Indian patent to extend market exclusivity.
  • The court has scheduled the next hearing for August 19, 2025 to review written statements and further submissions on sales and export issues.